Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaem...

Descripción completa

Detalles Bibliográficos
Autores: Bellido, Virginia, Martínez, Julia, Calvo, Fernando, Villarroel, Aida, Lecumberri, Edurne, Moreno, Juan, Morillas, Carlos, Rodrigo, Silvia, Izarra, Aitziber, Lecube Torelló, Albert
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/84869
Acceso en línea:https://doi.org/10.1007/s13300-022-01237-9
http://hdl.handle.net/10459.1/84869
Access Level:acceso abierto
Palabra clave:Dapagliflozin
Sodium-glucose cotransporter 2 inhibitors
Diabetes mellitus
Cardiometabolic risk factors
Therapeutic inertia
id ES_c4bb049a8dcf168cdc272ee11fd9e592
oai_identifier_str oai:recercat.cat:10459.1/84869
network_acronym_str ES
network_name_str España
repository_id_str
spelling Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical ComplicationsBellido, VirginiaMartínez, JuliaCalvo, FernandoVillarroel, AidaLecumberri, EdurneMoreno, JuanMorillas, CarlosRodrigo, SilviaIzarra, AitziberLecube Torelló, AlbertDapagliflozinSodium-glucose cotransporter 2 inhibitorsDiabetes mellitusCardiometabolic risk factorsTherapeutic inertiaDapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.Springer Nature202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1007/s13300-022-01237-9http://hdl.handle.net/10459.1/84869http://hdl.handle.net/10459.1/84869reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.1007/s13300-022-01237-9Diabetes Therapy, 2022, vol. 13, p. 873-888.cc-by-nc (c) Virgnia Bellido et. al., 2022.info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc/4.0/oai:recercat.cat:10459.1/848692026-05-29T05:05:01Z
dc.title.none.fl_str_mv Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
title Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
spellingShingle Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Bellido, Virginia
Dapagliflozin
Sodium-glucose cotransporter 2 inhibitors
Diabetes mellitus
Cardiometabolic risk factors
Therapeutic inertia
title_short Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
title_full Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
title_fullStr Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
title_full_unstemmed Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
title_sort Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
dc.creator.none.fl_str_mv Bellido, Virginia
Martínez, Julia
Calvo, Fernando
Villarroel, Aida
Lecumberri, Edurne
Moreno, Juan
Morillas, Carlos
Rodrigo, Silvia
Izarra, Aitziber
Lecube Torelló, Albert
author Bellido, Virginia
author_facet Bellido, Virginia
Martínez, Julia
Calvo, Fernando
Villarroel, Aida
Lecumberri, Edurne
Moreno, Juan
Morillas, Carlos
Rodrigo, Silvia
Izarra, Aitziber
Lecube Torelló, Albert
author_role author
author2 Martínez, Julia
Calvo, Fernando
Villarroel, Aida
Lecumberri, Edurne
Moreno, Juan
Morillas, Carlos
Rodrigo, Silvia
Izarra, Aitziber
Lecube Torelló, Albert
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dapagliflozin
Sodium-glucose cotransporter 2 inhibitors
Diabetes mellitus
Cardiometabolic risk factors
Therapeutic inertia
topic Dapagliflozin
Sodium-glucose cotransporter 2 inhibitors
Diabetes mellitus
Cardiometabolic risk factors
Therapeutic inertia
description Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1007/s13300-022-01237-9
http://hdl.handle.net/10459.1/84869
http://hdl.handle.net/10459.1/84869
url https://doi.org/10.1007/s13300-022-01237-9
http://hdl.handle.net/10459.1/84869
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1007/s13300-022-01237-9
Diabetes Therapy, 2022, vol. 13, p. 873-888.
dc.rights.none.fl_str_mv cc-by-nc (c) Virgnia Bellido et. al., 2022.
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv cc-by-nc (c) Virgnia Bellido et. al., 2022.
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418927095808000
score 15.811543

Similares en LA Referencia